Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses…. ANDA 208204, held by Taro. Betamethasone Valerate.
As of Nov 16, 2026, ANDA 208204 (Betamethasone Valerate), held by Taro, was first approved by FDA on May 24, 2017, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Betamethasone valerate foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 24, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Betamethasone Valerate0.12% · aerosol, foam;topical | Betamethasone Valerate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters